Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response

P. J. Hesketh; S. M. Grunberg; J. Herrstedt; R. de Wit; R. J. Gralla; A. D. Carides; A. Taylor; J. K. Evans; K. J. Horgan

doi:10.1007/s00520-005-0914-4

Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response

Supportive Care in Cancer ◽

10.1007/s00520-005-0914-4 ◽

2006 ◽

Vol 14 (4) ◽

pp. 354-360 ◽

Cited By ~ 63

Author(s):

P. J. Hesketh ◽

S. M. Grunberg ◽

J. Herrstedt ◽

R. de Wit ◽

R. J. Gralla ◽

...

Keyword(s):

Treatment Response ◽

Nausea And Vomiting ◽

Phase Iii ◽

Two Phase ◽

Phase Iii Trials ◽

Nk1 Antagonist ◽

Combined Data

Download Full-text

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy

Supportive Care in Cancer ◽

10.1007/s00520-009-0737-9 ◽

2009 ◽

Vol 18 (9) ◽

pp. 1171-1177 ◽

Cited By ~ 91

Author(s):

Paul J. Hesketh ◽

Matti Aapro ◽

James C. Street ◽

Alexandra D. Carides

Keyword(s):

Risk Factors ◽

Standard Of Care ◽

Nausea And Vomiting ◽

Phase Iii ◽

Current Standard ◽

Two Phase ◽

Antiemetic Treatment ◽

Phase Iii Trials ◽

Treatment Analysis

Download Full-text

Effect of age on treatment outcome to palonosetron (PALO) plus 1-day dexamethasone (DEX) for the prevention of nausea and vomiting in women receiving anthracycline plus cyclophosphamide (AC)-based chemotherapy: A meta-analysis of two phase III trials.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e19536 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e19536-e19536

Author(s):

L. Celio ◽

E. Bonizzoni ◽

E. Bajetta ◽

S. Sebastiani ◽

T. Perrone ◽

...

Keyword(s):

Treatment Outcome ◽

Meta Analysis ◽

Nausea And Vomiting ◽

Phase Iii ◽

Two Phase ◽

Phase Iii Trials ◽

Effect Of Age

Download Full-text

Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials

Supportive Care in Cancer ◽

10.1007/s00520-012-1558-9 ◽

2012 ◽

Vol 21 (2) ◽

pp. 565-573 ◽

Cited By ~ 18

Author(s):

Luigi Celio ◽

Erminio Bonizzoni ◽

Emilio Bajetta ◽

Silvia Sebastiani ◽

Tania Perrone ◽

...

Keyword(s):

Single Dose ◽

Individual Patient Data ◽

Meta Analysis ◽

Patient Data ◽

Nausea And Vomiting ◽

Phase Iii ◽

Two Phase ◽

Phase Iii Trials ◽

Effect Of Age

Download Full-text

3056 POSTER Effect of Palonosetron Plus 1-day Dexamethasone (DEX) on the Prevention of Delayed Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy (MEC): a Pooled Analysis of Two Phase III Trials

European Journal of Cancer ◽

10.1016/s0959-8049(11)71129-7 ◽

2011 ◽

Vol 47 ◽

pp. S239 ◽

Cited By ~ 1

Author(s):

L. Celio ◽

E. Bonizzoni ◽

E. Bajetta ◽

S. Sebastiani ◽

T. Perrone ◽

...

Keyword(s):

Pooled Analysis ◽

Emetogenic Chemotherapy ◽

Nausea And Vomiting ◽

Phase Iii ◽

Moderately Emetogenic Chemotherapy ◽

Two Phase ◽

Delayed Nausea ◽

Phase Iii Trials

Download Full-text

Long‐term evaluation of combined prolonged‐release oxycodone and naloxone in patients with moderate‐to‐severe chronic pain: pooled analysis of extension phases of two Phase III trials

Neurogastroenterology & Motility ◽

10.1111/nmo.12463 ◽

2014 ◽

Vol 26 (12) ◽

pp. 1792-1801 ◽

Cited By ~ 17

Author(s):

M. Blagden ◽

J. Hafer ◽

H. Duerr ◽

M. Hopp ◽

B. Bosse

Keyword(s):

Chronic Pain ◽

Pooled Analysis ◽

Phase Iii ◽

Prolonged Release ◽

Two Phase ◽

Phase Iii Trials ◽

Severe Chronic Pain ◽

Term Evaluation

Download Full-text

Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.14581 ◽

2017 ◽

Vol 32 (1) ◽

pp. 68-72 ◽

Cited By ~ 9

Author(s):

C. Paul ◽

L. Guenther ◽

H. Torii ◽

H. Sofen ◽

R. Burge ◽

...

Keyword(s):

Quality Of Life ◽

Severe Psoriasis ◽

Phase Iii ◽

Two Phase ◽

Quality Of Life Measures ◽

Related Quality ◽

Phase Iii Trials

Download Full-text

Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials

Seminars in Oncology ◽

10.1016/s0093-7754(01)90297-0 ◽

2001 ◽

Vol 28 ◽

pp. 4-9 ◽

Cited By ~ 26

Author(s):

F SHEPHERD

Keyword(s):

Quality Of Life ◽

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Two Phase ◽

Phase Iii Trials

Download Full-text

Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.02.013

European Urology ◽

10.1016/j.eururo.2018.05.016 ◽

2018 ◽

Vol 74 (3) ◽

pp. e69-e70

Author(s):

Niven Mehra ◽

David Dolling ◽

Johann de Bono

Keyword(s):

Prostate Cancer ◽

Plasma Cell ◽

Phase Iii ◽

Castration Resistant Prostate Cancer ◽

Two Phase ◽

Cell Free Dna ◽

Dna Concentration ◽

Castration Resistant ◽

Free Dna ◽

Phase Iii Trials

Download Full-text

Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials

Ophthalmology ◽

10.1016/j.ophtha.2013.02.034 ◽

2013 ◽

Vol 120 (10) ◽

pp. 2013-2022 ◽

Cited By ~ 450

Author(s):

David M. Brown ◽

Quan Dong Nguyen ◽

Dennis M. Marcus ◽

David S. Boyer ◽

Sunil Patel ◽

...

Keyword(s):

Macular Edema ◽

Diabetic Macular Edema ◽

Phase Iii ◽

Long Term Outcomes ◽

Two Phase ◽

Phase Iii Trials

Download Full-text

Two Phase III trials show bevacizumab benefit for ovarian cancer

Oncology Times UK ◽

10.1097/01.otu.0000399898.13794.88 ◽

2011 ◽

Vol 8 (7) ◽

pp. 4

Author(s):

&NA;

Keyword(s):

Ovarian Cancer ◽

Phase Iii ◽

Two Phase ◽

Phase Iii Trials

Download Full-text